Precision Oncology | R&D methods of RGCC

Research and development methods

RGCC is actively engaged in research and development activities aimed at identifying, developing, and evaluating potential cancer therapies, diagnostics, and biomarkers. Our work focuses on identifying genes and proteins that may respond to drug treatments by leveraging a combination of molecular biological and cytogenetic methods, including:

Microarrays
Array comparative genomic hybridization (ArrayCGH RGCC)
Fluorescence in situ hybridization (FISH)
Next-generation sequencing NGS

For drug targets located on the cell membrane, RGCC's scientists are continuously working on developing fully human monoclonal antibodies. These antibodies are rigorously assessed for efficacy using well-established analytical methods, including:

Flow cytometry
Fluorescence-Activated Cell Sorting (FACS)
Viability assays
Surface Plasmon Resonance

Additionally, we apply advanced computational techniques to design and validate various potential molecules that target intracellular drug targets. To evaluate potential therapeutic responses and for specific drug response testing, we use in silico methods for drug design and discovery.

Subsequent phases entail biochemical testing to confirm the product's affinity with the corresponding protein or gene. For targets with small molecular weights and prior to further cell-based assays, we employ evaluation methods such as:

IC₅₀ (Half Maximal Inhibitory Concentration)
Surface Plasmon Resonance
Nuclear Magnetic Resonance (NMR)

These analyses encompass cell viability and cytotoxicity methods as well as comprehensive gene and protein expression analyses to validate therapeutic potential. At every stage of development, our processes are carefully monitored to ensure method efficiency and reliability to advance precision oncology.

Liquid biopsies offer a groundbreaking alternative to traditional biopsies, transforming cancer testing and research. In contrast to traditional biopsies, which focus on a single, localized area of the body, liquid biopsies collect data from distant (metastatic) sites, as well.

This non-invasive method examines multiple biomarkers, circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and cancer-associated proteins. Liquid biopsy testing enables early detection, treatment assessment, and continuous monitoring of tumor progression on a wide range of cancer types. Liquid biopsy helps generate a comprehensive picture of genetic health.

Explore our latest research and development articles to receive more information about our scientific progress and techniques.

RGCC's research articles

Circulating Tumor Cell (CTC) Testing

Circulating Tumor Cells (CTCs) are cancer cells that detach from the primary site and enter the bloodstream or lymphatic system. CTCs are clinically relevant cells as they are capable of driving metastases. The analysis of CTCs through liquid biopsy testing provides valuable information to support clinical decision-making.

CTC analyses enable genomic analysis and profiling through the evaluation of additional layers of information of the tumor cells. RGCC uses CTCs as a core component of its liquid biopsy-based approach to cancer monitoring and treatment guidance.

Circulating Tumor DNA (ctDNA) Testing

Circulating Tumor DNA (ctDNA) is a specific subset of cfDNA that originates exclusively from cancer cells. Tumors release ctDNA into the bloodstream either through cell death or active secretion.

Although ctDNA usually represents only a small fraction of the total cfDNA, it carries the genetic mutations and alterations specific to the tumor. This makes ctDNA a powerful tool for liquid biopsy, supporting early cancer detection, monitoring of treatment response, and identification of resistance mutations.

Next Generation Sequencing (NGS)

Next Generation Sequencing (NGS) is an advanced liquid biopsy technique that provides analysis of both DNA and RNA. It’s a huge upgrade over traditional methods like Sanger sequencing, which could only read one DNA fragment at a time. RGCC is using this method with its cancer blood test CAMBISeq, which analyzes over 500 genes that our scientists use as biomarkers to assess their sensitivity to immunotherapy or targeted therapy, supporting fully personalized oncology care.

RGCC Tests

At RGCC, we offer a whole suite of advanced diagnostic tests to help:

Produce personalized patient profiles for cancer treatment
Detect early signs of developing cancer
Monitor existing cancers
Follow-up monitoring for possible cancer metastasis

Our tests reveal personalized and granular levels of detail for patients and their specialists on the type of therapeutic drugs and natural substances that can be used to achieve the best outcomes for cancer treatment.

Our tests use our innovative liquid biopsy technique, which uses a blood sample from the patient to carry out analyses.

Discover RGCC tests

Innovative Technologies

There is no one-size-fits-all solution for chronic disease. Every patient and their condition are different, and each person responds in their own unique way. Our team of multidisciplinary scientists combines groundbreaking research with best-in-class technology to develop supportive approaches to patients.

Personalized approaches hold enormous potential to address previously unmet medical needs. Our dedicated team of scientists is actively working to turn this potential into reality by developing a range of autologous innovations aimed at supporting those affected by chronic diseases, including cancer.

Learn more